Soluble urokinase plasminogen activator receptor measurements: Influence of sample handling

International Journal of Biological Markers

Volumn 16, Issue 4, 2001, Pages 233-239

  Riisbro, Rikke ^a   Christensen, I J ^a   Hogdall C ^a   Brunner N ^a   Hogdall E ^a  

^a FINSEN LABORATORY   (Denmark)

Author keywords

EDTA plasma; Sample handling; Serum; Soluble urokinase plasminogen activator receptor; suPAR

Indexed keywords

BIOLOGICAL MARKER; EDETIC ACID; UROKINASE RECEPTOR;

ADULT; ARTICLE; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FROZEN SECTION; HUMAN; HUMAN EXPERIMENT; LABORATORY TEST; NORMAL HUMAN; PLASMA; PREMENOPAUSE; PROTEIN BLOOD LEVEL; SERUM; STORAGE; THAWING;

EID: 0035715545     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460080101600402     Document Type: Article

References (26)

1. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase
2. The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants
3. Plasminogen activators, tissue degradation, and cancer
4. Domain interplay in the urokinase receptor - Requirement for the third domain in high affinity ligand binding and demonstration of ligand contact sites in distinct receptor domains
5. A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors
6. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain
7. Cell-surface acceleration of urokinase-catalyzed receptor cleavage
8. Cellular glycosylphosphatidylinositol-specific phospholipase D regulates urokinase receptor shedding and cell surface expression
9. ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients
10. Domain 1 of the urokinase receptor (uPAR) is required for uPAR-mediated cell binding to vitronectin
11. A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer
12. Soluble receptor for urokinase plasminogen activator in both full-length and a cleaved form is present in high concentration in cystic fluid from ovarian cancer
13. The receptor for urokinase-type plasminogen activator and urokinase is translocated from two distinct intracellular compartments to the plasma membrane on stimulation of human neutrophils
14. The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria
15. Enhanced release of soluble urokinase receptor by endothelial cells in contact with peripheral blood cells
16. Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer
17. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases
18. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients
19. Plasma urokinase receptor levels in patients with colorectal cancer: Relationship to prognosis
20. Prognostic importance of the soluble plasminogen activator receptor, suPAR, in plasma from rectal cancer patients
21. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: Increased concentrations in rheumatoid arthritis
22. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection
23. Measurements of soluble urokinase plasminogen activator receptor in serum
24. OVX1 radioimmunoassay results are dependent on the method of sample collection and storage
25. Stability of YKL-40 concentration in blood samples